Supreme Court Questions High Markups on Cancer Drugs, Proposes Uniform Pricing Cap
The Supreme Court has raised concerns over the steep markups on cancer and other essential medicines, highlighting cases where drugs supplied to retailers for around Rs 2,700 are sold to patients at MRPs up to Rs 27,000. The court questioned the exclusion of many medicines from the Drugs (Prices Control) Order, 2013, and suggested a uniform 16 percent cap on retail margins. It also criticized corporate hospitals for mandating purchases from in-house pharmacies, which may burden patients and taxpayers, especially under government healthcare schemes. The Karnataka government has urged the Centre to intervene and regulate pricing disparities and trade margins for high-value drugs.
First-hand measurement across 15 sources
We measured how 15 outlets covered this story. Coverage leans balanced overall (Left 11%, Centre 89%, Right 0%). Overall sentiment is negative (36/100). Lens Score 63/100.
Outlets measured: zeenews, freepressjournal, thehindu, thetelegraph, indiatoday, economictimes, news18, moneycontrol, and 7 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 8 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (28–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thehindu broke this story on 27 Sept, 04:17 pm. Other outlets followed.